Semaglutide Improves eGFR Slope vs. Placebo Regardless of Baseline HbA1c and Blood Pressure in People With Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

被引：0
|
作者：
Cherney, David [1 ]
Bosch-Traberg, Heidrun [2 ]
Hadjadj, Samy [3 ]
Kuhlman, Anja B. [2 ]
Rasmussen, Soren [2 ]
Tuttle, Katherine R. [5 ,6 ]
Heerspink, Hiddo J. L. [4 ]
机构：
[1] Univ Hlth Network, Toronto, ON, Canada
[2] Novo Nordisk, Soborg, Denmark
[3] Inst Thorax, Nantes, France
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Univ Washington, Spokane, WA USA
[6] Providence Washington, Spokane, WA USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
SA-PO265
引用
收藏
页码：675 / 675
页数：1
相关论文
共 50 条
  • [21] Greater Reductions in HbA1c and Body Weight with Once-Weekly Semaglutide vs. Comparators across Baseline BMI Subgroups: A Post Hoc Analysis of SUSTAIN 1-5 and 7-10
    Aroda, Vanita R.
    Frenkel, Ofir
    Frias, Juan P.
    Hindsberger, Charlotte
    Gylvin, Silas H.
    Le Roux, Carel
    Madsbad, Sten
    DIABETES, 2020, 69
  • [22] Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
    Wang, Jingyu
    Yang, Juhong
    Jiang, Wenhui
    Liu, Wenyan
    Shen, Zewei
    Gao, Zhongai
    Chang, Baocheng
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5157 - 5166
  • [23] SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES
    Bellary, S.
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. Gaarsdal
    Leiter, L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 34 : E6 - E7
  • [24] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6
    Seufert, J.
    Desouza, C.
    Kirk, A. R.
    Lawson, J.
    Lingvay, I.
    Sondergaard, A. L.
    Bain, S. C.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 252
  • [25] SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. G.
    Leiter, L. A.
    EUROPEAN HEART JOURNAL, 2017, 38 : 819 - 819
  • [26] Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6
    Verma, S.
    Husain, M.
    Madsen, C.
    Leiter, L. A.
    Rajan, S.
    Vilsboll, T.
    Rasmussen, S.
    Libby, P.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2479 - 2479
  • [27] Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6
    Verma, S.
    Husain, M.
    Madsen, C. M.
    Leiter, L. A.
    Rajan, S.
    Vilsboll, T.
    Rasmussen, S.
    Libby, P.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 253 - 254
  • [28] Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
    Pratley, Richard E.
    Crowley, Matthew J.
    Gislum, Mette
    Hertz, Christin L.
    Jensen, Thomas B.
    Khunti, Kamlesh
    Mosenzon, Ofri
    Buse, John B.
    DIABETES THERAPY, 2021, 12 (04) : 1099 - 1116
  • [29] Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
    Richard E. Pratley
    Matthew J. Crowley
    Mette Gislum
    Christin L. Hertz
    Thomas B. Jensen
    Kamlesh Khunti
    Ofri Mosenzon
    John B. Buse
    Diabetes Therapy, 2021, 12 : 1099 - 1116
  • [30] A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes
    Morgan Bron
    Craig Wilson
    Penny Fleck
    Diabetes Therapy, 2014, 5 : 521 - 534
12345